Allogene prices $175M public offering of 87.5M shares at $2.00 per share

Allogene Therapeutics, Inc.

Offering of 87,500,000 shares at $2.00/share; gross proceeds ~$175M before discounts and expenses.
Underwriters granted 30-day option to buy up to 13,125,000 additional shares at same price.
Closing expected on or about April 16, 2026, subject to customary conditions.
Net proceeds for general corporate purposes including clinical trials and R&D.
Goldman Sachs, Jefferies, and TD Cowen act as joint bookrunners; Piper Sandler and William Blair also joint bookrunners.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.